Abstract 3245
Background
Chronic myeloid leukemia (CML) is a malignant clonal hematopoietic disorder characterized by a translocation between chromosomes 9 and 22 leading to the production of BCR-ABL fusion protein. This fusion produces mainly two variants, namely b3a2 and b2a2, rarely are other transcripts detected. To date, the exact role of these transcript variants are unknown and has shown mixed results. The objective of this study is to study the clinical-hematological profile and major molecular response rates (MMR) at 1 year in relation to b2a2 and b3a2 transcripts in CML-CP.
Methods
After approval from the institutional ethics committee, the data of patients attending medical oncology department from January 2014 to December 2015 (2 years) were collected and analyzed. A total of 154 patients were diagnosed with CML and 140 of them were in chronic phase (CP).
Results
Among 140 patients, males accounted for 88 (62%) and b3a2 type was seen in 99 patients (71%). Baseline parameters like hemoglobin, white cell count, platelet count, Sokal scoring, and EUTOS risk are shown in Table below. Follow up data was not available for 2 and 9 patients in b2a2 and b3a2 type, respectively.Table: 1099P
Parameter (N = 140) | B2a2 (n = 41) | B3a2 (n = 99) | P value |
---|---|---|---|
Mean Hemoglobin mg/dl SEM | 9.6 0.31 | 9.8 0.2 | 0.6 NS |
Mean Total Leucocyte Count (X109) SEM | 166 16.3 | 185 9.8 | 0.3 NS |
Mean Platelet Count (X109) SEM | 379 3.57 | 440 2.42 | 0.16 NS |
Sokal risk (%) Low Intermediate High | 3 (7) 20 (49) 18 (44) | 7 (7) 40 (40) 52 (53) | 0.63 NS |
EUTOS risk (%) Low High | 12 (30) 29 (70) | 53 (52) 47 (47) | 0.011 Significant |
MMR at 1 year (%) | 63 | 52 | 0.21 NS |
SEM: Standard Error of Mean After 1 year of therapy with Imatinib, 63% in b2a2 and 52% in b3a2 type achieved MMR (p-value 0.21). Twenty patients (14%) were evaluated for kinase domain resistance mutations (17 in b3a2 and 3 in b2a2). Seven out of 17 patients in b3a2 and none in b2a2 type had detectable mutations. Phase migration to accelerated or blast phase occurred in 3 (7%) and 9 (9%) in b2a2 and b3a2 transcript types respectively.
*SEM: Standard Error of Mean After 1 year of therapy with imatinib, 63% in b2a2 and 52% in b3a2 type achieved MMR (p-value 0.21). Twenty patients (14%) were evaluated for kinase domain resistance mutations (17 in b3a2 and 3 in b2a2). Seven out of 17 patients in b3a2 and none in b2a2 type had detectable mutations. Phase migration to accelerated or blast phase occurred in 3 (7%) and 9 (9%) in b2a2 and b3a2 transcript types, respectively.
Conclusions
There is no statistically significant difference between the two transcripts in relation to baseline hematological parameters. Patients with b2a2 type had higher EUTOS score at presentation. Despite this, at the end of 12 months, MMR rates were similar between b2a2 and b3a2 transcript types.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Siva K Prasad.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3020 - Circulating tumor DNA (ctDNA) analysis depicts mechanisms of resistance and tumor response to BRAF inhibitors in BRAF-mutant non-small cell lung cancer (NSCLC)
Presenter: Sandra Ortiz - Cuaran
Session: Poster Display session 1
Resources:
Abstract
1271 - A large scale prospective concordance study of oncogene driver detection between plasma- and tissue-based NGS analysis in advanced non-small cell lung cancer (NSCLC).
Presenter: Ryo Itotani
Session: Poster Display session 1
Resources:
Abstract
1132 - Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)
Presenter: Aaron Cohen
Session: Poster Display session 1
Resources:
Abstract
1502 - An exploratory analysis of on-treatment ctDNA measurement as a potential surrogate for overall survival for atezolizumab benefit in the OAK Study
Presenter: David Gandara
Session: Poster Display session 1
Resources:
Abstract
3912 - Disease monitoring of EGFR mutation-positive NSCLC patients via circulating tumor DNA
Presenter: Wei Fang Hsu
Session: Poster Display session 1
Resources:
Abstract
3856 - Incidence of T790M in NSCLC patients progressed to gefitinib, erlotinib, and afatinib: a study on circulating tumor DNA
Presenter: Romano Danesi
Session: Poster Display session 1
Resources:
Abstract
1330 - Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-line pemetrexed-based therapy in patients with non-squamous non-small cell lung cancer
Presenter: Xiaoxia Chen
Session: Poster Display session 1
Resources:
Abstract
3512 - Carcinoembryonic Antigen of Cerebrospinal Fluid Predict Prognosis of Leptomeningeal Metastasis from Non-Small Cell Lung Cancer
Presenter: Junjie Zhen
Session: Poster Display session 1
Resources:
Abstract
3852 - Liquid biopsy in clinical pratice of Non-Small-Cell-Lung Cancer (NSCLC): a multi-institutional experience
Presenter: Giovanna De Maglio
Session: Poster Display session 1
Resources:
Abstract
1205 - A Phase III Study Comparing SB8, a Proposed Bevacizumab Biosimilar, and Reference Bevacizumab in Patients with Metastatic or Recurrent Non-squamous NSCLC
Presenter: Martin Reck
Session: Poster Display session 1
Resources:
Abstract